Enliven Therapeutics, Inc. · NASDAQ:ELVN
Kunkel Lori Anne sold 10,000 Enliven Therapeutics, Inc. shares (Form 4)
Traded Jul 6, 2026 · Filed Jul 8, 2026
On Jul 6, 2026, Kunkel Lori Anne (Director) sold 10,000 Enliven Therapeutics, Inc. shares at an average US$50.49 for US$505K under a trading plan, leaving 41,884 shares. Filed Jul 8, 2026 (Form 4).
- Sold
- 10,000 shares
- Price
- US$50.49 average (US$49.98 to US$50.84)
- Value
- US$505K
- Holding after
- 41,884 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Director
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Jul 6, 2026 | Common Stock | Sale | 4,111 | US$49.98 | 47,773 | Direct |
| Jul 6, 2026 | Common Stock | Sale | 5,889 | US$50.84 | 41,884 | Direct |
Source
Related
- Enliven Therapeutics, Inc.
- Kunkel Lori Anne
- Enliven Therapeutics, Inc. shareholders
- Form 4 · Kunkel Lori Anne · Jun 9, 2026
- Form 4 · Garland J. Scott · Oct 5, 2026
- Form 4 · Hohl Benjamin · Sep 21, 2026
- Form 4 · Collins Helen Louise · Sep 21, 2026
- Form 4 · Hohl Benjamin · Aug 19, 2026
- Form 4 · Collins Helen Louise · Aug 19, 2026